Interview with Alex Mayweg, partner at Versant Ventures and president of Ridgeline, a Versant Ventures Discovery Engine – Located in the Technologiepark Basel
“We make no compromises in creating the highest potential Company”
Versant Ventures has a strong history in building successful companies such as Therachon, Black Diamond or CRISPR Therapeutics. We talked to Alex Mayweg, partner at Versant Ventures in Basel, about the beauty of Versant Ventures discovery engine Ridgeline Therapeutics, translating science into successful drug development programs and the future of drug discovery.
BioVersys receives €20 million in EU financing to support ...
Monte Rosa Therapeutics raises $95M in series C funding roun...
Cellestia - a leading pioneer in modulating gene expression ...
Bottneuro among Forbes “30 Spin-offs To Watch 2021 DACH”
10 Jahre Technologiepark Basel – Treiber der Innovation